One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.1016/j.clml.2019.07.090
Copy DOI Publication Date: Aug 28, 2019 | |
 Citations: 3 |
Affiliation: Agios Pharmaceuticals (United States), Northwestern University, The University of Texas MD Anderson Cancer Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituti di Ricovero e Cura a Carattere Scientifico, Princess Margaret Cancer Centre, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Royal Perth Hospital, City Of Hope National Medical Center, University of Oxford, Massachusetts General Hospital, Hôpital Saint-Louis, University Hospital Ulm, Yale Cancer CenterMutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
